Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 13,39 € (+46,02 %). La mediana es de 13,39 € (+46,02 %).
| Comprar |
1 |
| Mantener |
0 |
| Vender |
0 |
Noticias Ir al feed de noticias
Trulieve Cannabis expects quarterly profit and sharp revenue decline
Trulieve Cannabis is expected to open the books for the quarter ended September 30, 2026, on November 5, 2026. Analysts on average expect earnings of $0.093 per share (prior year: -$0.140) on revenue of $221.9 million, a decline of 23.02% from $288.2 million a year earlier. For the current fiscal year, analysts forecast a mean loss per share of -$1.822 (prior year: -$0.610) and revenue of about $1.01 billion (prior year: $1.18 billion). » Más en finanzen.net
Datos financieros de la empresa
| (EUR) | junio de 2026 | YoY |
|---|---|---|
| Ingresos | 237,41 M | 7,37 % |
| Beneficio bruto | 142,2 M | 8,38 % |
| Beneficio neto | -355,8 M | 2943,27 % |
| EBITDA | -290,5 M | 447,80 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 1516,85 M € |
Número de acciones | 170,16 M |
Máximo/mínimo de 52 semanas | 11,85 € - 4,12 € |
| Dividendos | No |
Beta | 1,81 |
Ratio P/E | -4,08 |
Ratio PEG | 0,03 |
Ratio P/B | 2,51 |
Ratio P/S | 1,49 |
Perfil de la empresa
| Nombre | Trulieve Cannabis |
| CEO | Kimberly A. Rivers |
| Empleados | 5000 |
